XML 105 R91.htm IDEA: XBRL DOCUMENT v3.10.0.1
(Loss) Income Per Common Share (Computation Of Basic And Diluted (Loss) Income Per Common Share) (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2018
 [1]
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2017
 [2]
Sep. 30, 2017
 [2]
Jun. 30, 2017
 [2]
Mar. 31, 2017
 [2]
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Basic (loss) income per common share                              
Net (loss) income $ (776) $ 1,565 $ 226 $ (3,855) $ (3,007) $ 1,325 $ 3,163 $ 2,223 $ 2,897 $ 2,993 $ 2,347 $ 2,541 $ (2,840) $ 3,704 $ 10,778
Net (income) loss allocated to participating securities                         27 (63) (208)
Net income (loss) allocated to common shareholders                         $ (2,813) $ 3,641 $ 10,570
Basic weighted-average common shares outstanding                         36,412 33,008 31,855
Basic income (loss) per common share                         $ (0.08) $ 0.11 $ 0.33
Diluted (loss) income per common share                              
Net (loss) income $ (776) $ 1,565 $ 226 $ (3,855) $ (3,007) $ 1,325 $ 3,163 $ 2,223 $ 2,897 $ 2,993 $ 2,347 $ 2,541 $ (2,840) $ 3,704 $ 10,778
Net loss (income) allocated to participating securities                         27 (61) (202)
Net (loss) income allocated to common shareholders                         $ (2,813) $ 3,643 $ 10,576
Basic weighted-average common shares outstanding                         36,412 33,008 31,855
Effect of dilutive stock options and awards                           1,155 967
Diluted weighted-average common shares outstanding                         36,412 34,163 32,822
Diluted income (loss) per common share $ (0.02) $ 0.04 $ 0.01 $ (0.11) $ 0.09 $ 0.04 $ 0.09 $ 0.06 $ 0.09 $ 0.09 $ 0.07 $ 0.08 $ (0.08) [3] $ 0.11 [3] $ 0.32 [3]
[1] In December 2017 we completed our acquisition of JOTEC, which is also being operated as a wholly-owned subsidiary of CryoLife.
[2] In January 2016 we completed our acquisition of On-X Life Technologies Holdings, Inc., which is being operated as a wholly-owned subsidiary of CryoLife. In 2016 we also sold our HeRO Graft product line and our ProCol product line, and ceased sales of these products during 2016.
[3] We excluded stock options from the calculation of diluted weighted-average common shares outstanding if the per share value, including the sum of (i) the exercise price of the options and (ii) the amount of the compensation cost attributed to future services and not yet recognized, was greater than the average market price of the shares, because the inclusion of these stock options would be antidilutive to (loss) income per common share. For the year ended December 31, 2018 all stock options and awards were excluded from the calculation of weighted-average common shares outstanding as these would be antidilutive to the net loss. For the years ended December 31, 2017 and 2016 stock options to purchase 227,000 and 1,000 shares, respectively, were excluded from the calculation of diluted weighted-average common shares outstanding.